title: Treated prevalence rates of severe mental illness among HMO members.
abstract: OBJECTIVE
  The authors examined the extent to which health maintenance organizations (HMOs) enroll and provide services to people with severe mental illness.
  
  
  METHODS
  The automated pharmacy system of a large HMO identified members who had received a prescription for an antipsychotic drug or lithium during the two-year study period (1986 and 1987). These data, combined with data from a 2 percent random sample of HMO members and from medical records, were used to identify members who satisfied DSM-III-R criteria for schizophrenia and bipolar disorder. Treated prevalence rates derived from these data were compared with estimated treated prevalence data obtained in the National Institute of Mental Health's Epidemiologic Catchment Area (ECA) survey.
  
  
  RESULTS
  Although methodological complications and small sample sizes precluded a detailed comparison, the study found a significantly lower treated prevalence rate of schizophrenia among HMO members than in the ECA survey. The treated prevalence rate of bipolar disorder was also lower than the ECA rate, but the difference was not significant.
  
  
  CONCLUSIONS
  The differences in treated prevalence rates seemed to be the result of different study methodologies and factors influencing HMO membership. The results underscore the need for a comprehensive study of the course of severe mental illness among HMO members.
authors.affiliation: Center for Health Research, Kaiser Permanente Northwest Region, Portland, Oregon 97227.
authors.forename: R E
authors.initials: RE
authors.lastname: Johnson
authors.forename: B H
authors.initials: BH
authors.lastname: McFarland
mesh_terms: D000208:Acute Disease; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001714:Bipolar Disorder / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D008329:Managed Care Programs / Q000706:statistics & numerical data*; D008605:Mental Health Services / Q000706:statistics & numerical data*; D011569:Psychiatric Status Rating Scales; D012559:Schizophrenia / Q000175:diagnosis / Q000188:drug therapy*; D014481:United States
chemical_list: D014150:Antipsychotic Agents